License and Collaboration Agreements - (Details) $ / shares in Units, shares in Millions		1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 27, 2011 $ / shares shares	Jan. 31, 2016 USD ($) item	Jan. 31, 2015 USD ($)	Jan. 31, 2012 USD ($)	Mar. 31, 2016 USD ($) $ / shares	Mar. 31, 2015 USD ($)	Mar. 31, 2016 USD ($) $ / shares	Mar. 31, 2015 USD ($)	Jun. 30, 2015 USD ($) $ / shares
License and Collaboration Agreements [Abstract]
Upfront cash payment and other payments received under collaboration agreement							$ 6,000,000
License fee and other revenues		$ 300,000	$ 300,000		$ 266,096	$ 250,000	$ 302,324	$ 250,000	$ 1,000,000
Number of payments receivable per contract | item		1
License agreement date							May 09, 2006
Amendment agreement date							Dec. 27, 2011
Duration of warrant issued	5 years
Number of shares under five year warrant | shares	1
Shares to be purchased under warrant, par value | $ / shares	$ 0.01				$ 0.01		$ 0.01		$ 0.01
Shares to be purchased under warrant, exercise price | $ / shares	$ 8.00
Non-refundable cash payment received				$ 30,000,000
Clinical trial study, description							On July 28, 2015, UCB announced that the two Phase 3 EMBODY(TM) clinical trials for epratuzumab in SLE did not meet the primary clinical efficacy endpoints in either dose in both studies.